INTERPHEX and PDA Announce Sponsorship Agreement
INTERPHEX and the Parenteral Drug Association (PDA) announced a three-year sponsorship agreement, which aligns the objectives of both organizations to service key needs of the global pharmaceutical and biopharmaceutical industry.
International Pharmaceutical Expo (INTERPHEX), an annual trade event dedicated to the pharmaceutical and biopharmaceutical industry, and the Parenteral Drug Association (PDA) announced a three-year sponsorship agreement, which aligns the objectives of both organizations to service key needs of the global pharmaceutical and biopharmaceutical industry by driving innovation and advancement, the organizations report.
INTERPHEX brings together more than 12,000 industry professionals in pharmaceutical and biopharmaceutical manufacturing to learn, network, and source from the latest technology, equipment, education, and services. PDA is a global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical industry. Its mission is to develop scientifically sound, practical technical information and resources to advance science and regulation for the pharmaceutical and biopharmaceutical industry through the expertise of its more than 9,500 global members.
“Our Sponsorship of INTERPHEX reflects our support of the continued enhancement of industry learning and improvement, areas we find present at INTERPHEX,” stated Richard Johnson, president and CEO of PDA. “Non-profits and corporate entities can work together to leverage best practices, in real-time, to the benefit of our industry. Our collaboration with INTERPHEX is one example of this effort and we are pleased to move forward in this shared endeavor.”
PDA will be directly involved in developing the INTERPHEX conference programming, identifying speakers from industry and regulatory agencies, and developing a PDA sponsored cGMP Track. PDA members will have educational and networking opportunities including an exclusive Association Membership Lounge.
“A long-term Sponsorship with PDA, both on national and global levels, aligns us with thought leaders across the globe,” stated Bob Stewart, vice president of INTERPHEX. “By fostering alliances with successful non-profit organizations like PDA, we acknowledge our investment in the future of the biopharmaceutical industry, and ultimately deliver unrivaled opportunities for knowledge, interaction, and professional growth.”
INTERPHEX will be held March 18-20, 2014 at the Jacobs Javits Center in New York City.
Source: INTERPHEX and the Parenteral Drug Association (PDA)
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
